治疗定植金黄色葡萄球菌的父母对新生儿重症监护室新生儿传播的影响:一项随机临床试验
这项双盲RCT在巴尔的摩2个三级NICU纳入236名有S aureus定植父母的新生儿,父母随机接受鼻内莫匹罗星+2%氯己定浸渍布(活性治疗组117名)或鼻内凡士林+非药物肥皂布(安慰剂组119名)治疗5天。主要终点为90天内新生儿获得与父母基线菌株一致的S aureus定植,活性治疗组89名中13名(14.6%)vs 安慰剂组101名中29名(28.7%)发生一致定植(风险差-14.1%[95%CI -30.8%至-3.9%];HR 0.43[95.2%CI 0.16至0.79])。活性治疗组任何S aureus菌株获得率31.4%(28/89)vs 对照组45.5%(46/101)(HR 0.57[95%CI 0.31至0.88])。作者结论认为该初步试验显示治疗定植父母可显著减少新生儿一致定植,但需进一步研究重复这些发现并评估其普遍性。
要点
- 在2个三级NICU的初步RCT中,对S aureus定植父母使用鼻内莫匹罗星和2%氯己定浸渍布治疗5天,新生儿90天内获得与父母基线菌株一致定植的比例为14.6%(13/89)vs 安慰剂组28.7%(29/101),风险差-14.1%(95%CI -30.8%至-3.9%)。
- 活性治疗组任何S aureus菌株获得率为31.4%(28/89)vs 对照组45.5%(46/101),HR 0.57(95%CI 0.31至0.88)。
- 活性治疗组1名新生儿(1.1%)和对照组1名新生儿(1.0%)在定植前发生S aureus感染。
- 父母皮肤反应常见:活性治疗组4.8%,安慰剂组6.2%。
- 作者结论认为这是初步试验,需进一步研究重复这些发现并评估其普遍性。
适用人群与场景
- 纳入:在2个三级NICU中,有S aureus定植父母的新生儿(n=236随机)。
- 分析样本208名新生儿:55%男性;76%单胎;平均出生体重1985 g(SD 958 g);76%阴道产;父母平均年龄31岁(SD 7岁)。
诊断标准与关键阈值
- 主要终点:90天内新生儿获得与父母筛查时基线菌株一致的S aureus定植(一致定植)。
- 次要终点:新生儿获得任何S aureus菌株;新生儿S aureus感染。
处置流程与药物剂量
- 父母随机接受活性治疗:鼻内莫匹罗星和2%氯己定浸渍布,疗程5天(n=117)。
- 父母随机接受安慰剂:鼻内凡士林软膏和非药物肥皂布,疗程5天(n=119)。
- 研究期间:2014年11月7日至2018年12月13日。
研究设计与关键结果
- 研究类型:双盲随机临床试验,在巴尔的摩2个三级NICU进行;随机236名新生儿,208名纳入分析样本,其中18名失访;190名新生儿纳入分析。
- 主要终点:活性治疗组13/89(14.6%)vs 安慰剂组29/101(28.7%)发生一致S aureus定植;风险差-14.1%(95%CI -30.8%至-3.9%);HR 0.43(95.2%CI 0.16至0.79)。
- 关键次要终点:任何S aureus菌株获得,活性治疗组28/89(31.4%)vs 对照组46/101(45.5%);HR 0.57(95%CI 0.31至0.88)。
- 新生儿S aureus感染:活性治疗组1名(1.1%)vs 对照组1名(1.0%),均在定植前发生。
- 不良事件:父母皮肤反应活性治疗组4.8% vs 安慰剂组6.2%。
证据类型、等级与局限
- 证据类型:双盲随机临床试验(初步试验)。
- 局限:作者结论指出这是初步试验,需进一步研究重复这些发现并评估其普遍性。
对床旁实践的改变
- 作者认为,在这项初步试验中,对S aureus定植父母使用鼻内莫匹罗星和氯己定浸渍布与安慰剂相比,可显著减少新生儿获得与父母基线菌株一致的S aureus定植。
- 作者结论指出需进一步研究重复这些发现并评估其普遍性。
指南或共识出处
- ClinicalTrials.gov Identifier: NCT02223520
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Staphylococcus aureus is a leading cause of health care-associated infections in the neonatal intensive care unit (NICU). Parents may expose neonates to S aureus colonization, a well-established predisposing factor to invasive S aureus disease.
OBJECTIVE: To test whether treating parents with intranasal mupirocin and topical chlorhexidine compared with placebo would reduce transmission of S aureus from parents to neonates.
DESIGN, SETTING, AND PARTICIPANTS: Double-blinded randomized clinical trial in 2 tertiary NICUs in Baltimore, Maryland. Neonates (n = 236) with S aureus-colonized parent(s) were enrolled. The study period was November 7, 2014, through December 13, 2018.
INTERVENTIONS: Parents were assigned to intranasal mupirocin and 2% chlorhexidine-impregnated cloths (active treatment, n = 117) or petrolatum intranasal ointment and nonmedicated soap cloths (placebo, n = 119) for 5 days.
MAIN OUTCOMES AND MEASURES: The primary end point was concordant S aureus colonization by 90 days, defined as neonatal acquisition of an S aureus strain that was the same strain as a parental strain at time of screening. Secondary outcomes included neonatal acquisition of any S aureus strain and neonatal S aureus infections.
RESULTS: Among 236 randomized neonates, 208 were included in the analytic sample (55% male; 76% singleton births; mean birth weight, 1985 g [SD, 958 g]; 76% vaginal birth; mean parent age, 31 [SD, 7] years), of whom 18 were lost to follow-up. Among 190 neonates included in the analysis, 74 (38.9%) acquired S aureus colonization by 90 days, of which 42 (56.8%) had a strain concordant with a parental baseline strain. In the intervention and placebo groups, 13 of 89 neonates (14.6%) and 29 of 101 neonates (28.7%), respectively, acquired concordant S aureus colonization (risk difference, -14.1% [95% CI, -30.8% to -3.9%]; hazard ratio [HR], 0.43 [95.2% CI, 0.16 to 0.79]). A total of 28 of 89 neonates (31.4%) in the intervention group and 46 of 101 (45.5%) in the control group acquired any S aureus strain (HR, 0.57 [95% CI, 0.31 to 0.88]), and 1 neonate (1.1%) in the intervention group and 1 neonate (1.0%) in the control group developed an S aureus infection before colonization. Skin reactions in parents were common (4.8% intervention, 6.2% placebo).
CONCLUSIONS AND RELEVANCE: In this preliminary trial of parents colonized with S aureus, treatment with intranasal mupirocin and chlorhexidine-impregnated cloths compared with placebo significantly reduced neonatal colonization with an S aureus strain concordant with a parental baseline strain. However, further research is needed to replicate these findings and to assess their generalizability.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02223520.
参考来源
- Milstone AM, Voskertchian A, Koontz DW, et al. Effect of Treating Parents Colonized With Staphylococcus aureus on Transmission to Neonates in the Intensive Care Unit: A Randomized Clinical Trial. JAMA. 2020. PMID: 31886828. doi:10.1001/jama.2019.20785
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。